February 17, 2022 4:48pm

Cheaper and cheaper equities set the stage for an algorithmic rebound

Pre-open Indications: 2 HIT and 5 MISS

The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?

 

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

The Dow closed DOWN -623.09 points (-1.78%); the S&P closed DOWN -94.83 points (-2.12%) while the Nasdaq closed DOWN -407.38 points (-2.88%)

 

Henry’omics:

Indexes declined Thursday as the Russia-Ukraine conflict topped headlines.

For the week, the S&P 500 is little changed, the Nasdaq is up marginally and the Dow is down slightly on the week.

Economic Data Docket: weekly jobless claims numbers came in at 248,000, rising from the previous week and above the 218,000 expected, according to a Dow Jones estimate. Housing permits for January showed a surprise increase, but housing starts lagged expectations.

 

52-week lows:

  • bluebird bio (BLUE) all-time low of $6.32
  • Solid Biosciences (SLDB) all-time low of $1.03
  • Sage Therapeutics (SAGE) all-time low of $34.88
  • Editas Medicine (EDIT) all-time low of $15.46
  • Precigen (PGEN) all-time low of $2.06
  • Verastem (VSTM) all-time low of $1.26

 

RegMed Investors’ (RMi) pre-open: “damaged goods or is it time to consider near-term intentions? Experiencing few highs and mostly lows of the cell and gene therapy sector’s equities while many companies still haven’t recovered from last year” … https://www.regmedinvestors.com/articles/12305

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened negative at 1 up/65 downs, 7 flats and 1 acquired, stayed negative at the mid-day at 4/29, 1 flat and 1 acquired, ending with a negative close of 3/29, 1 flat and 1 acquired;

 

Pre-open indications: 2 Hit < Intellia Therapeutics (NTLA -$5.46), Voyager Therapeutics (VYGR -$0.19)> 5 MISS < BioLife Solutions (BLFS -$2.01), bluebird bio (BLUE -$0.33), Chinook Therapeutics (KDNY -$0.28), Global Blood Therapeutics (GBT -$1.44), Pluristem (PSTI +$0.02),

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares trading up +$0.07 with 700 shares traded after Wednesday’s -$0.06 (after being down -$0.98) with 420 shares traded after Tuesday’s flat again with 200 shares traded after Monday’s flat with 1,899 shares traded after

Last Friday’s -$0.02 with 1,739 shares traded after Thursday’s +$0.60 with 2,841 shares traded after Wednesday’s down -$0.61 (was as low as -$1.09) with 4,030 shares traded after Tuesday’s +$0.05 with 1,293 shares traded after Monday’s +$0.55 with 2,311 shares traded,

  • The previous Friday’s +$0.22 with 305 shares traded, Thursday’s flat ($0.00) with 3 shares traded, Wednesday’s down -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded after last Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and the previous Tuesday’s +$0.31 with 2,794 shares traded.

 

Key Metrics:

  • Thursday - Sector volume was LOW with 1 of the 4-upside having higher than the 3-month average volume with LOW volume of 6 of 29-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed down -3.01% and XBI closed down -4.26%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +4.03 points or +16.59% at 28.32

 

Jumping with share pricing momentum (4 of 4):

  • Bellicum Pharmaceuticals (BLCM +$0.31 after Wednesday’s +$0.14),
  • Biostage (BSTG +$0.06),
  • Applied Genetic Technologies (AGTC +$0.02),
  • Caladrius Biosciences (CLBS -$0.0006),

Hammered in today’s market (10 of 29):

  • Intellia Therapeutics (NTLA -$5.46 after Wednesday’s -$2.66, Tuesday’s +$8.21 and Monday’s -$1.11),
  • Ultragenyx (RARE -$3.94 after Wednesday’s -$2.38, Tuesday’s +$2.30 and Monday’s -$1.66),
  • CRISPR Therapeutic (CRSP -$3.36 after Wednesday’s +$1.00, Tuesday’s +$2.36 and Monday’s -$0.79),
  • Alnylam Pharmaceuticals (ALNY -$3.33),
  • Sage Therapeutics (SAGE -$2.33 after Wednesday’s -$7.59, Tuesday’s +$1.21 and Monday’s -$0.75),
  • Fate Therapeutics (FATE -$2.30 after Wednesday’s -$1.87, Tuesday’s +$1.49 and Monday’s -$1.41),
  • BioLife Solutions (BLFS -$2.01 after Wednesday’s -$1.17),
  • Vericel (VCEL -$1.89),
  • Global Blood Therapeutics (GBT -$1.44 after Wednesday’s -$2.41, Tuesday’s +$1.58 and Monday’s -$0.35),
  • Editas Medicine (EDIT -$1.03),

Closing Flat:

  • 1 –ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Thursday closed negative with 4 incliner, 29 decliners, 1 flat and 1 acquired
  • Wednesday closed negative with 8 incliner, 22 decliners, 4 flats and 1 acquired
  • Tuesday closed positive with 31 incliners, 1 decliner, 2 flat and 1 acquired
  • Monday (2/14) closed negative with 4 incliners, 28 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE: Cell and gene therapy sector stocks dived, twisting and turned-on Thursday following Wednesday’s headlines after jumping a day earlier after an apparent or superficial de-escalation of Russian advances in Ukraine.

We are just going with the flow as we trip and fall to the weekend …

Thursday's deep dive just gives me hives ...

Wednesday’s down “sliders’ were Sage Therapeutics (SAGE), Intellia Therapeutics (NTLA), Fate Therapeutics (FATE) and Ultragenyx (RARE) with a few “upsiders” being Global Blood Therapeutics (GBT), Bellicum Therapeutics (BLCM), Brainstorm Cell Therapeutics (BCLI), Mesoblast (MESO) and a surprise - Applied Genetic Technologies (AGTC)

Tuesday’s “sprinters” were Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Ultragenyx (RARE) with only 1 loser Applied Genetic technologies (AGTC) with ReNeuron (RENE.L) and Biostage (BSTG) flat

Monday closed down with just a few ups … Vericel (VCEL), Voyager therapeutics (VYGR), uniQure NV (QURE) and Caladrius Biosciences (CLBS) while the downs were numbered at 28.

Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.  

Earnings’ reporting:

  • AxoGen AXGN) – Tuesday, 2/22
  • Global Blood Therapeutics (GBT) – Wednesday, 2/23
  • Sage Therapeutics (SAGE), Thursday, 2/24
  • Ionis Pharmaceuticals (IONS) - Thursday, 2/24
  • Editas Medicine (EDIT) - Thursday, 2/24
  • Fate therapeutics, Monday, 2/28
  • Athersys (ATHX), Tuesday, 3/15

 

WHY do I keep analyzing Biostage (BSTG): I WAS there to experience the lack of investor prerogatives and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.